21.03
전일 마감가:
$20.75
열려 있는:
$21.11
하루 거래량:
2.93M
Relative Volume:
1.42
시가총액:
$2.11B
수익:
$352.57M
순이익/손실:
$-143.01M
주가수익비율:
-11.62
EPS:
-1.81
순현금흐름:
$-153.40M
1주 성능:
-0.66%
1개월 성능:
+25.48%
6개월 성능:
-14.27%
1년 성능:
-18.93%
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
BEAM
Beam Therapeutics Inc
|
21.03 | 2.13B | 352.57M | -143.01M | -153.40M | -1.81 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-28 | 업그레이드 | BofA Securities | Neutral → Buy |
2025-03-10 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
2025-01-29 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2024-10-16 | 개시 | Scotiabank | Sector Outperform |
2024-07-23 | 개시 | H.C. Wainwright | Buy |
2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
2023-03-21 | 개시 | Bernstein | Mkt Perform |
2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2022-12-13 | 개시 | Citigroup | Buy |
2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
2022-04-28 | 개시 | Credit Suisse | Neutral |
2022-01-05 | 개시 | Guggenheim | Buy |
2021-10-19 | 개시 | SVB Leerink | Outperform |
2021-09-24 | 재개 | Stifel | Buy |
2021-09-10 | 개시 | BofA Securities | Buy |
2021-05-11 | 개시 | Redburn | Buy |
2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2021-02-16 | 개시 | Wells Fargo | Overweight |
2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2021-01-06 | 개시 | Stifel | Hold |
2020-08-05 | 개시 | William Blair | Outperform |
2020-03-02 | 개시 | Barclays | Overweight |
2020-03-02 | 개시 | JP Morgan | Overweight |
2020-03-02 | 개시 | Jefferies | Buy |
2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
Is Beam Therapeutics Inc. a good long term investmentHigh-impact investment strategies - Autocar Professional
Beam Therapeutics Inc. Stock Analysis and ForecastUnstoppable trading performance - Autocar Professional
What drives Beam Therapeutics Inc. stock priceRapid-fire capital growth - Autocar Professional
Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail
Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company - MSN
What analysts say about Beam Therapeutics Inc. stockHigh-yield capital appreciation - jammulinksnews.com
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
(BEAM) Trading Report - news.stocktradersdaily.com
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? - MSN
H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT - MSN
Beam Therapeutics: A Base Editing Breakthrough With Catalysts to Ignite Value - AInvest
Beam Therapeutics’ BEAM-101 Shows Promising Results in Sickle Cell Disease Trial - MSN
Beam Therapeutics Acquires Early-Stage Life Sciences Firm - The Globe and Mail
H.C. Wainwright reiterates Buy rating on Beam Therapeutics stock at $80 target - Investing.com
Beam Therapeutics: A Contrarian Opportunity in Gene Editing Amid Russell Reconstitution - AInvest
Top 10 CRISPR Stocks to Buy Now - Insider Monkey
Beam Therapeutics Inc.(NasdaqGS: BEAM) dropped from Russell 3000 Value Index - MarketScreener
3 Promising Genomics Stocks to Keep an Eye On in 2025 - The Globe and Mail
BEAM-101 shows sustained benefits as treatment for sickle cell - Sickle Cell Disease News
Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases - Seeking Alpha
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? - Yahoo Finance
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - Yahoo Finance
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
BEAM Therapeutics’ SWOT analysis: base editing pioneer’s stock faces pivotal year - Investing.com
H.C. Wainwright reiterates buy rating on Beam Therapeutics stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates buy rating on Beam Therapeutics stock - Investing.com
Cathie Wood’s ARK ETFs adjust holdings, buying GitLab and Beam Therapeutics stock - Investing.com Nigeria
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clini - GuruFocus
Beam Therapeutics Announces New Data from BEACON Phase 1/2 - GlobeNewswire
Beam Therapeutics (BEAM) Reports Strong Results for Sickle Cell Therapy - GuruFocus
Beam reports positive results from sickle cell disease treatment - Seeking Alpha
Beam Therapeutics reports positive data from sickle cell therapy trial - Investing.com
Beam Therapeutics Reports Positive Update From Sickle Cell Disease Trial - MarketScreener
Beam Therapeutics reports positive data from sickle cell therapy trial By Investing.com - Investing.com Nigeria
Beam Therapeutics (BEAM) Releases Promising Data from BEACON Trial | BEAM Stock News - GuruFocus
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):